Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $43.20

Akero Therapeutics, Inc. (NASDAQ:AKRO) has earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $43.20.

A number of equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research report on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th.

Akero Therapeutics Stock Performance

NASDAQ:AKRO opened at $30.01 on Friday. The firm has a market capitalization of $2.08 billion, a PE ratio of -9.38 and a beta of -0.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The stock has a 50-day simple moving average of $26.86 and a two-hundred day simple moving average of $24.06. Akero Therapeutics has a 52-week low of $11.25 and a 52-week high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Analysts forecast that Akero Therapeutics will post -3.64 EPS for the current year.

Insider Transactions at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 1,738 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total value of $45,500.84. Following the sale, the chief executive officer now owns 605,417 shares of the company’s stock, valued at $15,849,817.06. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Catriona Yale sold 2,485 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $27.52, for a total value of $68,387.20. Following the completion of the sale, the insider now directly owns 75,294 shares of the company’s stock, valued at approximately $2,072,090.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Cheng sold 1,738 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $45,500.84. Following the transaction, the chief executive officer now directly owns 605,417 shares of the company’s stock, valued at $15,849,817.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 258,731 shares of company stock worth $7,020,729 in the last ninety days. Insiders own 7.94% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AKRO. Wellington Management Group LLP grew its stake in Akero Therapeutics by 247.7% in the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after acquiring an additional 2,053,028 shares during the period. Janus Henderson Group PLC grew its position in shares of Akero Therapeutics by 42.2% during the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after buying an additional 1,815,569 shares during the last quarter. Redmile Group LLC grew its position in shares of Akero Therapeutics by 67.5% during the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock valued at $46,951,000 after buying an additional 749,226 shares during the last quarter. Vanguard Group Inc. grew its position in Akero Therapeutics by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after purchasing an additional 584,875 shares during the last quarter. Finally, Long Focus Capital Management LLC lifted its stake in shares of Akero Therapeutics by 119.0% in the 2nd quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock worth $16,882,000 after acquiring an additional 391,000 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.